LARGE2

Across TCGA pan-cancer cohorts, LARGE2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LARGE2 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher LARGE2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LARGE2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and GBM show a favorable association.

BLCA, UCEC, and SKCM are the cancer types where LARGE2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.051	0.684	<.001	24	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	II,III,IV	0.808	0.543	.032	4	view →
GBM	DFS	Median	All	1.000	0.204	.042	3	view →
LIHC	OS	Median	All	0.188	0.669	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LARGE2–BLCA (OS)

Open the BLCA breakdown →